Stockscreener 앱 받기
3.30
0.61%
0.02
전일 마감가:
$3.28
열려 있는:
$3.33
하루 거래량:
1.16M
Relative Volume:
1.46
시가총액:
$740.32M
수익:
$596.48M
순이익/손실:
$123.72M
주가수익비율:
6.0175
EPS:
0.5484
순현금흐름:
$106.59M
1주 성능:
-9.59%
1개월 성능:
-20.29%
6개월 성능:
-0.60%
1년 성능:
-3.51%
1일 변동 폭
$3.22
$3.385
1주일 범위
$3.22
$3.61
52주 변동 폭
$2.215
$5.28
큐어백 Stock (CVAC) Company Profile
CVAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
3.30 | 740.32M | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
큐어백 Stock (CVAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-25 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 개시 | SVB Securities | Outperform |
| 2023-01-19 | 업그레이드 | UBS | Neutral → Buy |
| 2023-01-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-01-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-06-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Underperform |
| 2021-04-26 | 개시 | Guggenheim | Neutral |
| 2020-12-10 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-09-08 | 개시 | Credit Suisse | Neutral |
| 2020-09-08 | 개시 | Jefferies | Hold |
모두보기
큐어백 주식(CVAC)의 최신 뉴스
CureVac: The mid-term effect of pipeline pruning -February 21, 2025 at 08:16 am EST - Marketscreener.com
Is CureVac N.V. (CVAC) the Best Get Rich Fast Stock to Buy Now? - Insider Monkey
A History of Outperforming Analyst Forecasts and Beating the Odds: CureVac N.V (CVAC) - SETE News
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators - ACCESS Newswire
mRNA Pioneer CureVac Clinches Elite Innovation Status with 1,000-Patent Arsenal - StockTitan
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal year in vaccine race - MSN
CureVac Appoints Klaus Edvardsen as Chief Development Officer - ACCESS Newswire
JMP Securities Reiterates “Market Outperform” Rating for CureVac (NASDAQ:CVAC) - Defense World
CureVac (NASDAQ:CVAC) Shares Gap UpWhat's Next? - MarketBeat
Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch - Benzinga
CureVac (NASDAQ:CVAC) Trading Down 5.8%Time to Sell? - MarketBeat
Individual investors among CureVac N.V.'s (NASDAQ:CVAC) largest stockholders and were hit after last week's 6.1% price drop - Simply Wall St
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia - MSN
CureVac NV (FRA:5CV) Altman Z-Score : 3.43 (As of Feb. 01, 2025) - GuruFocus.com
CureVac NV (FRA:5CV) Momentum Rank : 7 (As of Feb. 01, 2025) - GuruFocus.com
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - ACCESS Newswire
CureVac (NASDAQ:CVAC) Shares Sold by Ballentine Partners LLC - Defense World
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update - ACCESS Newswire
Brokers Offer Predictions for CureVac FY2025 Earnings - Defense World
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update - ACCESS Newswire
22,946 Shares in CureVac (NASDAQ:CVAC) Bought by Barclays PLC - Defense World
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 - ACCESS Newswire
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer - ACCESS Newswire
FY2025 EPS Estimates for CureVac Raised by Leerink Partnrs - MarketBeat
Companies Like CureVac (NASDAQ:CVAC) Are In A Position To Invest In Growth - Yahoo Finance
CureVac (NASDAQ:CVAC) Stock Price Down 3.7%What's Next? - MarketBeat
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update - ACCESS Newswire
CureVac (NASDAQ:CVAC) Shares Up 4.7%Should You Buy? - MarketBeat
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster TestingCureVac (NASDAQ:CVAC) - Benzinga
Jane Street Group LLC Has $235,000 Stock Position in CureVac (NASDAQ:CVAC) - Defense World
Geode Capital Management LLC Lowers Position in CureVac (NASDAQ:CVAC) - Defense World
CureVac NV (FRA:5CV) 50-Day SMA : €2.91 (As of Jan. 11, 2025) - GuruFocus.com
CVAC (CureVac NV) 14-Day RSI : 68.17 (As of Jan. 10, 2025) - GuruFocus.com
CureVac (NASDAQ:CVAC) Trading 5.7% HigherHere's What Happened - MarketBeat
Why CureVac (CVAC) Shares Are Volatile - Benzinga
CureVac: Latest GBM Data Bodes Well For Next Program Check Point (NASDAQ:CVAC) - Seeking Alpha
Why CureVac (CVAC) Stock Is Moving - Benzinga
CureVac (NASDAQ:CVAC) Shares Gap DownHere's What Happened - MarketBeat
CureVac (NASDAQ:CVAC) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Why CureVac (CVAC) Stock Is Rising - Benzinga
Vaccine stocks gain amid uptick in flu, COVID-19, RSV (CVAC:NASDAQ) - Seeking Alpha
Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25% - Simply Wall St
Short Interest in CureVac (NASDAQ:CVAC) Declines By 6.4% - MarketBeat
CureVac (NASDAQ:CVAC) Trading Up 3.6% – Still a Buy? - Defense World
CureVac (NASDAQ:CVAC) Stock Quotes, Forecast and News Summary - Benzinga
CureVac (NASDAQ:CVAC) Stock Price Up 3.6%Here's What Happened - MarketBeat
Discover 3 US Penny Stocks With Market Caps Over $200M - Simply Wall St
CureVac (NASDAQ:CVAC) Trading Up 4.7%What's Next? - MarketBeat
CureVac (NASDAQ:CVAC) Shares Down 5.5%What's Next? - MarketBeat
CureVac's SWOT analysis: mRNA pioneer's stock faces oncology pipeline hurdles - Investing.com
2 Small-Cap Stocks Set to Shine in a Bull Market - Benzinga
큐어백 (CVAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):